Supernus Pharmaceuticals

Supernus Pharmaceuticals

HQ location
Rockville, United States
Launch date
Market cap
$1.7b
Enterprise value
$1.3b
Share price
$31.52 SUPN
  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor

€0.0

round
investor investor

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
*

$150m

Post IPO Debt
Total Funding000k
NEA
NEA(exited)
OrbiMed
OrbiMed(exited)
Abingworth
Abingworth(exited)

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
USD2021202220232024202520262027
Revenues0000000000000000000000000000
% growth11 %15 %(9 %)9 %(4 %)9 %10 %
EBITDA0000000000000000000000000000
% EBITDA margin21 %22 %18 %26 %27 %31 %35 %
Profit0000000000000000000000000000
% profit margin9 %9 %-11 %1 %(4 %)2 %
EV0000000000000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000
R&D % of revenue16 %11 %15 %16 %---

Source: Company filings or news article, Equity research estimates

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by Supernus Pharmaceuticals

Edit
Adamas Pharmaceuticals
ACQUISITION by Supernus Pharmaceuticals Oct 2021
SAGE Therapeutics
ACQUISITION by Supernus Pharmaceuticals Jun 2025
Biscayne NeuroTherapeutics
ACQUISITION by Supernus Pharmaceuticals Sep 2018